Clik here to view.
Cordis CSO Rogers departs for HeartFlow
Campbell Rogers is leaving his post as chief scientific officer for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. – a role created for him in July 2006 – to take the chief medical officer job at...
View ArticleClik here to view.
Cordis CSO Rogers departs for HeartFlow | Personnel Moves
Campbell Rogers is leaving his post as chief scientific officer for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. – a role created for him in July 2006 – to take the chief medical officer job at...
View ArticleClik here to view.
St. Jude launches Asian FFR economics study
St. Jude Medical (NYSE:STJ) is launching a study to examine the economics of coronary interventions using fractional flow reserve in Japan, China, India, Korea, and Australia. The analysis, based on...
View ArticleClik here to view.
Mixed results for HeartFlow’s CT-based FFR tests for coronary artery disease
HeartFlow’s non-invasive fractional flow reserve technology failed to meet pre-determined rates of accuracy in a recent clinical trial, but researchers and clinicians remained optimistic that the new...
View ArticleClik here to view.
GI Dynamics swaps CEOs | Personnel Moves
GI Dynamics (ASX:GID) said it’s replacing Stuart Randle as CEO with Michael Dale, the former chief at ATS Medical until its 2010 acquisition by Medtronic (NYSE:MDT). Randle will stay on as a member of...
View ArticleClik here to view.
HeartFlow wins FDA OK for non-invasive FFR system
By Brad Perriello and Mark Hollmer HeartFlow yesterday said it won de novo clearance from the FDA for its non-invasive cloud-based cardiac imaging technology, which CEO Dr. John Stevens told...
View ArticleClik here to view.
FDA green lights Stimwave’s mini spinal cord stimulator | Regulatory news for...
FDA gives the green light to Stimwave's mini spinal cord stimulator December 3, 2014 by Mark Hollmer Stimwave Technologies won the FDA’s 510(k) clearance for a wireless neuromodulation anti-pain...
View ArticleClik here to view.
JenaValve taps medtech vet Keltjens for interim CEO | Personnel Moves
JenaValve tapped a medtech veteran with a string of successful exits behind him as interim chairman & CEO, replacing another medical device vet, David Drachman, after just 7 months. Drachman, who...
View ArticleClik here to view.
SNN invests in Michelson’s Series B | Medtech funding for the week of...
Smith & Nephew gets in on Michelson Diagnostics Series B round February 16, 2015 by Brad Perriello Smith & Nephew put down the cornerstone in the 1st tranche of Michelson Diagnostics’ $3.8...
View ArticleClik here to view.
Boston Scientific taps ex-Covidien CFO Dockendorff, Hologic CEO MacMillan for...
Boston Scientific (NYSE:BSX) said yesterday that it named a pair of big-name medical device executives to its board of directors. Marlborough, Mass.-based Boston Scientific said it added the former...
View ArticleClik here to view.
Toshiba interim CEO Muromachi to stay on | Personnel Moves
Toshiba (TYO:6502) proposed the company keep interim CEO Masahi Muromachi on as permanent chief exec after 8 officials resigned due to their roles in an accounting scandal, Japanese media reports....
View ArticleClik here to view.
HeartFlow study shows reduced unnecessary ICA with FFRct
HeartFlow presented data from a clinical trial of its FFRct analysis that showed a significant reduction in unnecessary invasive coronary angiography after evaluation with the device. The data was...
View ArticleClik here to view.
ESC Congress 2015: St. Jude, HeartFlow tout FFR-guided PCI
The European Society of Cardiology Congress conference wrapped up this week in London. Here’s a roundup of news from the overseas meeting of interventional cardiologists, dominated by data on...
View ArticleClik here to view.
TCT 2015: HeartFlow’s CT-based FFR lowers costs, improves quality of life
A non-invasive test of cardiac function made by HeartFlow lowered the cost of care and delivered improved quality of life scores compared to standard care, according to a study presented yesterday at...
View ArticleClik here to view.
FDA finalizes Class II status for HeartFlow’s FFRct software
HeartFlow‘s non-invasive CT-guided fractional flow reserve software has been reclassified as a class II medical device by the FDA, according to a posting from the agency published today. The FDA...
View ArticleClik here to view.
Boston Scientific’s Synergy stent at 2 years | ACC 2016 roundup
Evolve II: 2-year data for Boston Scientific’s Synergy stent Boston Scientific‘s (NYSE:BSX) Synergy stent showed non-inferiority to its Promus Element Plus device after 12 months, according to data...
View ArticleClik here to view.
HeartFlow launches new FFRct cardiac imaging platform
HeartFlow said today that it’s launching a new version of its cardiac imaging platform, which uses algorithms to generate a 3D model of blood as it flows through the heart. Redwood City, Calif.-based...
View ArticleClik here to view.
UK’s NICE set to recommend Heartflow’s FFRct
The U.K.’s National Institute for Health and Care Excellence last Friday released guidance supporting HeartFlow‘s FFRct technology, which uses algorithms to generate 3D models of blood flows and can...
View ArticleClik here to view.
HeartFlow wins Japanese approval for FFRct tech
HeartFlow said today it won approval from the Japanese Ministry of Health, Labour and Welfare for its HeartFlow FFRct technology, which uses algorithms to generate 3D models of blood flows and can help...
View ArticleClik here to view.
HeartFlow wins nod from U.K. healthcare board
The U.K.’s National Institute for Health & Care Excellence issued final guidance on HeartFlow‘s FFRct technology, which uses algorithms to generate 3D models of blood flows and can help diagnose...
View Article
